Avec plus de 1000 employés dans le monde, HORIBA Medical est une filiale du groupe japonais HORIBA.
Présent dans plus de 110 pays répartis sur les 5 continents, la Société est l’un des leaders mondiaux du marché de l’hématologie.
Avec plus de 30 000 laboratoires équipés, nos instruments bénéficient d’une renommée planétaire dans le domaine de Diagnostic In Vitro en contribuant dès aujourd’hui à préparer la santé de demain.
Prêt à relever les défis de demain ? Devenez "Horibarien" ! Ensemble, construisons l’avenir.
Design and commercialization of Laboratory Analyzers, Hematology, Clinical Chemistry, Global Hematology Solution, Point of care, Peri Analytic, R&D, Diagnostic IVD, Automatons, Production, Distribution, New Technologies et Customer Support
Discover the innovative Yumizen H550 & H500 analyzers at Medlab Middle East 2025! 🌟
Designed for precision and efficiency, these automated hematology analyzers deliver CBC, DIFF, and ESR results with cutting-edge CoRA technology. Plus, detect malaria and dengue with iDoubleDiff and enjoy seamless support with Yumicare.
Perfect for labs of all sizes, oncology care, blood banks, and more!
📍 Visit HORIBA at booth Z4.E10 to learn more about transforming hematology diagnostics.
HORIBA#myMedlab#medlabmiddleeast2025#HORIBA#Yumizen
We announce that HORIBA will rebrand based on its mid-long term management plan. 𝐇𝐎𝐑𝐈𝐁𝐀 𝐌𝐞𝐝𝐢𝐜𝐚𝐥's social media and website will gradually be renamed to 𝐇𝐎𝐑𝐈𝐁𝐀 𝐟𝐨𝐫 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞.
We will continue to provide our latest news under the new name to all our stakeholders involved in healthcare. Leveraging our expertise, core technologies, and global network, we aim to develop unique solutions and transform healthcare. We kindly ask for your understanding and continued support by following our page.
https://lnkd.in/ek5Jn3ui
We announce that HORIBA will rebrand based on its mid-long term management plan. 𝐇𝐎𝐑𝐈𝐁𝐀 𝐌𝐞𝐝𝐢𝐜𝐚𝐥's social media and website will gradually be renamed to 𝐇𝐎𝐑𝐈𝐁𝐀 𝐟𝐨𝐫 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞.
We will continue to provide our latest news under the new name to all our stakeholders involved in healthcare. Leveraging our expertise, core technologies, and global network, we aim to develop unique solutions and transform healthcare. We kindly ask for your understanding and continued support by following our page.
https://lnkd.in/ek5Jn3ui
Looking for our corporate news in France? You are on our business showcase page now, but we also have a dedicated LinkedIn company page! The company page brings you information about our headquarters in France such as job offers, job fairs, corporate events and news, employee initiatives... and more! Visit and follow the company page "HORIBA Medical FRANCE (HORIBA ABX SAS)":
https://lnkd.in/eNpN6D4R#HoribaMedicalFrance#HoribaAbxSas#recruitment
In November, our Regulatory Affairs team welcomed around fifteen students from the Faculty of Pharmacy at the University of Montpellier, to present the European and international regulatory requirements applicable to in vitro diagnostic medical devices (IVDMD).
The Faculty of Pharmacy at the University of Montpellier trains students on the quality and regulatory aspects of medicines, medical devices, and in vitro diagnostic medical devices. The presentation given at HORIBA is part of their academic curriculum and will be included in their end-of-year assessment.
We are proud to support the education of future healthcare professionals. Several students have completed their end-of-studies internship in the Regulatory Affairs department in the past, and we look forward to continuing this collaboration.
HORIBA is committed to nurturing the next generation of experts who will shape the future of healthcare.
En novembre, notre équipe des Affaires Réglementaires a reçu une quinzaine d’étudiants de la Faculté de Pharmacie de Montpellier, pour leur présenter les exigences réglementaires européennes et internationales applicables aux dispositifs médicaux de diagnostic in vitro (DMDIV).
La faculté de Pharmacie de Montpellier forme les étudiants sur les aspects qualité et réglementaire des médicaments, dispositifs médicaux et dispositifs médicaux de diagnostic in vitro. La présentation donnée au sein d’HORIBA fait partie de leur cursus scolaire, et sera intégrée à leur évaluation de fin d’année.
Nous sommes fiers de soutenir l'éducation des futurs professionnels de la santé. Plusieurs étudiants ont par le passé réalisé leur stage de fin d’études dans le service des Affaires Réglementaires, et nous nous réjouissons de poursuivre cette collaboration.
HORIBA s'engage à encourager la prochaine génération d'experts qui façonneront l'avenir des soins de santé.
University of Montpellier
This month's clinical case is a female aged 70 with fatigue and weakness diagnosed with Acute Myeloid Leukemia (M5) - Monocytic. See the detailed test results, microscopy findings, and how the HORIBA Yumizen H2500 hematology analyzer assists in diagnosis here: https://lnkd.in/eRagzmVq#AML#AMoL#leukemia#hematology#ClinialLab#MedicalLab#Hematology
HORIBA wishes you happy holidays and a Joy and Fun new year! We are so thankful for all of you and your endless support. We look forward to a successful 2025!
Mark your calendar! HORIBA is excited to join Medlab Middle East 2025. We'll be at booth Z4. E10, Hall 4, from February 3 until 6.
Medlab Middle East website: https://bit.ly/40oyNu9#Medlab#MiddleEast2025
#HemeInsights ✅ 𝐐𝐮𝐢𝐳 𝐀𝐧𝐬𝐰𝐞𝐫:
Target cell, C) Thalassemia
Target cells are red blood cells that have the appearance of a shooting target with a bullseye. In optical microscopy, these cells appear to have a dark center (a central, hemoglobinized area) surrounded by a white ring (an area of relative pallor). Clinical details may include anemia-like symptoms with a reduced MCV.
Dig deeper into the blood and blood disorders in our hematology newsletter, which focuses on blood morphology bringing you case studies & slide reviews, hemostasis, technologies, clinical advancements, and quizzes: https://lnkd.in/ez5usnQp
#HemeInsights Look at this slide, can you name the cell? What possible clinical details would this patient likely have? Share your guess in the comments and stay tuned for the answer next week!
A) Glandular fever
B) Nothing abnormal
C) Thalassemia
Dig deeper into the blood and blood disorders in our hematology newsletter, which focuses on blood morphology bringing you case studies & slide reviews, hemostasis, technologies, clinical advancements, and quizzes: https://bit.ly/4fK8ea3
100th Anniversary of the Birth of Founder Masao Horiba
December 1, 2024, marks the 100th anniversary of the birth of the late Masao Horiba, founder of the HORIBA Group.
Masao Horiba is known as a pioneer of student ventures in Japan, having founded the HORIBA Radio Laboratory on October 17, 1945, while studying at the Faculty of Science at Kyoto Imperial University.
He established HORIBA, Ltd. in 1953, and with his inquisitive mind, he refined his unique technology and led the company to become a global niche top company in the field of analysis and measurement. Today, the HORIBA Group has 50 group companies in 29 countries and regions around the world and has grown into a leading company in analysis and measurement systems that operates globally.
The HORIBA Group's corporate motto, "Omoshiro Okashiku," was established by Masao Horiba in 1978, the 25th anniversary of the founding of HORIBA Ltd. This corporate motto is translated into "Joy and Fun " in English, and familiar with the employees beyond Japan. Our company motto embodies our founder's wish that "people should take pride in their work, where they will spend the most active years of their lives, and by working excitingly, they can increase their life satisfaction and live more fun and interesting lives."
Inheriting the wishes embodied in our company motto, in 2023, the 70th anniversary of the company incorporating, we have set a vision of "Joy and Fun for All" and a mission of "Creating the future with solutions based on HONMAMON and diversity."
On the occasion of the 100th anniversary of Masao Horiba's birth, we will once again keep our founder's wishes in our hearts and embody the "Joy and Fun" that each of our approximately 8,700 "HORIBARIANS*" working around the world envisions, striving to create a world where all life can live abundantly.
*HORIBARIAN: We consider all people who work at HORIBA to be part of the same family, and we call them HORIBARIANs.
#HORIBA#MasaoHoribas100thBirthday#OurFuturehttps://lnkd.in/gEbTv2mM
